BIOCYTOGEN-B (02315) has announced its 2025 performance forecast. Based on preliminary calculations by the company's finance department, the Group expects to achieve annual operating revenue between RMB1.369 billion and RMB1.389 billion in 2025. This represents an increase of RMB388 million to RMB408 million compared to the same period last year, a year-on-year rise of 39.61% to 41.65%.

The Group anticipates achieving a net profit attributable to owners of the parent company in the range of RMB162 million to RMB182 million for the full year 2025. This signifies an increase of RMB129 million to RMB149 million compared to the prior year period, surging by 384.26% to 443.88% year-on-year.

Furthermore, the Group forecasts a net profit attributable to owners of the parent company, after deducting non-recurring gains and losses, of RMB105 million to RMB125 million for 2025. This compares to an increase of RMB81.9513 million to RMB102 million over the same period last year, representing a substantial year-on-year growth of 356.81% to 443.88%.

The announcement attributes this robust performance to the continuous expansion in overseas markets, coupled with the recovery and rebound of the domestic biopharmaceutical industry, which have driven the company's operating revenue to achieve rapid growth.

High-barrier technological advantages have ensured that business gross margins remain at elevated levels, while lean management initiatives have further enhanced operational efficiency, leading to a rapid improvement in the company's overall profitability.